In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding
Annals of Internal Medicine · 2023
DOI: 10.7326/j23-0016 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Efstratios Koutroumpakis und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, Texas, USA (E.K., A.D.). Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Texas MD Anderson Cancer Center, Houston, Texas, USA (E.K., A.D.).
Zitieren
APA
Koutroumpakis, E., & Deswal, A. (2023). In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding. Annals of Internal Medicine. https://doi.org/10.7326/j23-0016
Vancouver
Koutroumpakis E, Deswal A. In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding. Annals of Internal Medicine. 2023. doi:10.7326/j23-0016
BibTeX
@article{Koutroumpakis2023,
author = {Koutroumpakis, Efstratios and Deswal, Anita},
title = {In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding},
journal = {Annals of Internal Medicine},
year = {2023},
doi = {10.7326/j23-0016}
}
EUVIMED